Orladeyo Now Reimbursable in Japan via National Health Insurance

Orladeyo Now Reimbursable in Japan via National Health Insurance

291896

Orladeyo Now Reimbursable in Japan via National Health Insurance

Japan’s National Health Insurance System (NHI) has approved the addition of Orladeyo (berotralstat), an oral preventive treatment for hereditary angioedema (HAE) attacks, to its drug price list. This means that the NHI will reimburse hospitals and pharmacies prescribing Orladeyo to a certain amount under national health insurance programs. “Our goal is to bring Orladeyo to HAE patients around the world who want a new oral, once-daily option to prevent their attacks,” Jon Stonehouse, president and…

You must be logged in to read/download the full post.